Cargando…
Cladribine and cytarabine in children refractory high risk multisystem Langerhans cell histiocytosis
There is no uniform regimen for refractory Langerhans cell histiocytosis (LCH). We retrospectively described patients with refractory multisystem and risk organ involvement LCH treated with the low-dose (Ara-c, 100 mg/m(2)/d × 5day; 2-CDA, 5 mg/m(2)/d × 5day) chemotherapy (LDC) and the intermediate-...
Autores principales: | Wang, Wenqian, Ge, Jian, Ma, Honghao, Lian, Hongyun, Cui, Lei, Zhao, Yunze, Li, Zhigang, Wang, Tianyou, Zhang, Rui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481182/ https://www.ncbi.nlm.nih.gov/pubmed/37681174 http://dx.doi.org/10.1016/j.heliyon.2023.e19277 |
Ejemplares similares
-
Improvement in Pituitary Imaging After Targeted Therapy in Three Children with BRAF-Mutated Langerhans Cell Histiocytosis with Pituitary Involvement
por: Yang, Ying, et al.
Publicado: (2020) -
Effectiveness of cladribine therapy in patients with pulmonary Langerhans cell histiocytosis
por: Grobost, Vincent, et al.
Publicado: (2014) -
Multisystem Langerhans Cell Histiocytosis in Adult
por: Garg, Anubhav, et al.
Publicado: (2012) -
Multisystemic Langerhans cell histiocytosis in an adult
por: Hegemann, Marie-Valerie, et al.
Publicado: (2017) -
Multisystem Langerhans Cell Histiocytosis in an infant
por: Ji, William, et al.
Publicado: (2021)